Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Teva Targets $113 Billion In Branded Sales With Dozens Of Pending Applications

This article was originally published in The Pink Sheet Daily

Executive Summary

The Israeli drug maker reports sales rose by 25 percent in 2009, and takes aim at a plethora of generic opportunities

You may also be interested in...



Advisory Committee To Review Disease Modifying Claim For Teva's Parkinson's Drug

In large early Parkinson's trial, one dose worked but another did not. Review will show how results from innovative trial will be received by FDA.

Advisory Committee To Review Disease Modifying Claim For Teva's Parkinson's Drug

In large early Parkinson's trial, one dose worked but another did not. Review will show how results from innovative trial will be received by FDA.

Teva's Laquinimod Meets Primary Endpoint In First Phase III Study

Favorable safety profile may differentiate Teva's laquinimod from competing oral multiple sclerosis therapies.

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS070233

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel